Neuronostics, the Bristol-based MedTech company developing a clinically validated digital biomarker platform, has raised £3M in a funding round co-led by Empirical Ventures and The FSE Group. The round also includes participation from British Business Bank’s South West Investment Fund, Ascension Ventures, QantX, New Wave Venture Partners, and Angel Investors Bristol. The equity investment was...